Issues related to development of new antiseizure treatments
about
Advances on genetic rat models of epilepsy.Role of GluK1 kainate receptors in seizures, epileptic discharges, and epileptogenesisEpilepsy therapy development: technical and methodologic issues in studies with animal modelsThe potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.Gene therapy in epilepsy-is it time for clinical trials?Epilepsy management: newer agents, unmet needs, and future treatment strategies.Tau reduction prevents disease in a mouse model of Dravet syndromeAtomic basis for therapeutic activation of neuronal potassium channels.The challenge and promise of anti-epileptic therapy development in animal models.Staged anticonvulsant screening for chronic epilepsy.Potent Anti-seizure Effects of Locked Nucleic Acid Antagomirs Targeting miR-134 in Multiple Mouse and Rat Models of Epilepsy.Inhibition of glutamate decarboxylase (GAD) by ethyl ketopentenoate (EKP) induces treatment-resistant epileptic seizures in zebrafish.Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.Antagomirs targeting microRNA-134 increase hippocampal pyramidal neuron spine volume in vivo and protect against pilocarpine-induced status epilepticus.Development and pharmacologic characterization of the rat 6 Hz model of partial seizures.Synthesis and Determination of Lipophilicity, Anticonvulsant Activity, and Preliminary Safety of 3-Substituted and 3-Unsubstituted N-[(4-Arylpiperazin-1-yl)alkyl]pyrrolidine-2,5-dione Derivatives.Complex alterations in microglial M1/M2 markers during the development of epilepsy in two mouse models.The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach?Not all that glitters is gold: A guide to critical appraisal of animal drug trials in epilepsy.Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening.
P2860
Q27024903-F63ACF97-69BA-4144-BD85-9B061929B464Q28238788-1B05A541-8E47-4D72-9C19-6A697356DAB9Q30543230-3ACE1537-0500-43B2-9C6C-E388AEFD4E76Q30576758-BE6B73DA-26DE-4962-B723-DCF95A6C35F1Q34410588-36B5C2E0-7DC5-488E-923B-9DED1AAF4512Q34445004-2D114D51-501A-46F6-B780-70F3C839F744Q35115219-41DA18F0-C8C0-4AA7-B30F-CCA90419DBFAQ36033788-D7A9D293-1D33-4F62-8695-1776D6F58EFCQ37214420-2FF44410-44CB-4ACA-BF05-CD3AEB0B2044Q37577880-C56E4DF7-CBD4-46E5-9725-19BCD3C5105FQ37718027-D9814B40-930B-4EA4-8EC5-5E659D69F5CAQ38642231-B8ADB11A-F107-4469-BC34-103933032F71Q38746272-6FFE4A3D-CF58-4A9E-B4C7-30063C3AD0DFQ44393750-2897B4AB-D431-4A58-A442-A6018027B841Q46375658-CB17B7BD-A548-47D7-B65F-3F66CCCE972EQ47633070-144B5EF4-C757-49EE-A7AA-D6BA17B56E47Q48244586-1D1AC883-DC11-4F6A-95B9-0D59AB75E4ADQ48581800-23A146E5-2407-4F29-BB89-99513D47C81AQ51818804-E6CFB058-14BE-420C-95BD-02ADC7878E43Q55471525-89780058-0B49-459E-A623-A2BCB708349D
P2860
Issues related to development of new antiseizure treatments
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Issues related to development of new antiseizure treatments
@en
Issues related to development of new antiseizure treatments.
@nl
type
label
Issues related to development of new antiseizure treatments
@en
Issues related to development of new antiseizure treatments.
@nl
prefLabel
Issues related to development of new antiseizure treatments
@en
Issues related to development of new antiseizure treatments.
@nl
P2093
P2860
P356
P1433
P1476
Issues related to development of new antiseizure treatments
@en
P2093
Elinor Ben-Menachem
H Steve White
Jeffrey L Noebels
Karen S Wilcox
Marc A Dichter
Michael A Rogawski
Michael D Privitera
Roger J Porter
Solomon L Moshé
Tracy Dixon-Salazar
P2860
P356
10.1111/EPI.12296
P478
54 Suppl 4
P577
2013-08-01T00:00:00Z